Acorda Therapeutics Names Ruhi Kahn as Vice President, Business Development
Last update: 8/5/2009 7:00:03 AM
HAWTHORNE, N.Y., Aug 05, 2009 (BUSINESS WIRE) -- Acorda Therapeutics, Inc. (ACOR) today announced that Ruhi Khan has been named Vice President, Business Development, reporting to President and CEO Ron Cohen, M.D.
Previously, Ms. Khan was the Executive Director, Business Development at Acorda. Before joining the Company, Ms. Khan was the Senior Director of Business Development at Lexicon Pharmaceuticals. While at Lexicon, she led the business development function for both in-licensing and out-licensing of programs, research stage collaborations, technology assessments, spin-outs and other strategic initiatives. She was also responsible for market research and market analysis for clinical product candidates. Prior to that, Ms. Khan was a Director at Fidelity Biosciences, the biotech venture capital investment division at Fidelity Investments; in that capacity, she had operational management responsibilities at EnVivo Pharmaceuticals, a biotech company focused on the development of therapies for central nervous system disorders. Ms. Khan has a Bachelor of Arts from Harvard College and a Master of Business Administration from the Wharton School.
"I'm delighted to announce the promotion of Ruhi Khan to Vice President of Business Development," Dr. Cohen said. "Ruhi's first assignment after joining Acorda was to lead our process to obtain a commercialization partner for Fampridine-SR outside the U.S. She did an outstanding job of executing this process and concluding a great deal with an optimal partner, Biogen Idec. I expect Ruhi to continue to be a major contributor to Acorda's future successes as we work to capitalize on business development opportunities and build shareholder value."
---------------------------
G and A expenses is now higher than R and D expenses. Wonderful. Pass me a free lunch. |
